Eukaryotic Translation Initiation Factor 5A (EIF5A) Regulates Pancreatic Cancer Metastasis by Modulating RhoA and Rho-associated Kinase (ROCK) Protein Expression Levels.
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with an overall survival rate of less than 5%. The poor patient outcome in PDAC is largely due to the high prevalence of systemic metastasis at the time of diagnosis and lack of effective therapeutics that target disseminated cells. The fact that the underlying mechanisms driving PDAC cell migration and dissemination are poorly understood have hindered drug development and compounded the lack of clinical success in this disease. Recent evidence indicates that mutational activation of K-Ras up-regulates eIF5A, a component of the cellular translational machinery that is critical for PDAC progression. However, the role of eIF5A in PDAC cell migration and metastasis has not been investigated. We report here that pharmacological inhibition or genetic knockdown of eIF5A reduces PDAC cell migration, invasion, and metastasis in vitro and in vivo. Proteomic profiling and bioinformatic analyses revealed that eIF5A controls an integrated network of cytoskeleton-regulatory proteins involved in cell migration. Functional interrogation of this network uncovered a critical RhoA/ROCK signaling node that operates downstream of eIF5A in invasive PDAC cells. Importantly, eIF5A mediates PDAC cell migration and invasion by modulating RhoA/ROCK protein expression levels. Together our findings implicate eIF5A as a cytoskeletal rheostat controlling RhoA/ROCK protein expression during PDAC cell migration and metastasis. Our findings also implicate the eIF5A/RhoA/ROCK module as a potential new therapeutic target to treat metastatic PDAC cells.
From the Department of Pathology, Moores Cancer Center, University of California, San Diego, La Jolla, California 92093.
Ken
K
Fujimura
From the Department of Pathology, Moores Cancer Center, University of California, San Diego, La Jolla, California 92093.
Sunkyu
S
Choi
From the Department of Pathology, Moores Cancer Center, University of California, San Diego, La Jolla, California 92093.
Meghan
M
Wyse
From the Department of Pathology, Moores Cancer Center, University of California, San Diego, La Jolla, California 92093.
Jan
J
Strnadel
From the Department of Pathology, Moores Cancer Center, University of California, San Diego, La Jolla, California 92093.
Tracy
T
Wright
From the Department of Pathology, Moores Cancer Center, University of California, San Diego, La Jolla, California 92093 rklemke@ucsd.edu.
Richard
R
Klemke
D045744:Cell Line, Tumor; D055785:Gene Knockdown Techniques; D006801:Humans; D009362:Neoplasm Metastasis; D010190:Pancreatic Neoplasms / Q000473:pathology*; D010448:Peptide Initiation Factors / Q000235:genetics / Q000502:physiology*; D016601:RNA-Binding Proteins / Q000235:genetics / Q000502:physiology*; D054460:rho-Associated Kinases / Q000378:metabolism*; D000097574:Eukaryotic Translation Initiation Factor 5A
D010448:Peptide Initiation Factors; D016601:RNA-Binding Proteins; D054460:rho-Associated Kinases; D000097574:Eukaryotic Translation Initiation Factor 5A
Rho (Rho GTPase); pancreatic cancer; translation control; translation initiation factor; tumor cell biology; tumor metastasis